Begriffe, Krankheiten, Einrichtungen u.v.m., verknüpft mit dem zuständigen Bereich.
Im Menüpunkt "Übersicht" sind Einrichtungen unter verschiedenen Gesichtspunkten gruppiert: Kliniken, Abteilungen, Institute, Zentrale Einrichtungen und ähnliches.
Most important recent publications
Bohnert J, Szymaniak-Vits M, Schuster S, Kern WV. Efflux inhibition by selective serotonin reuptake inhibitors in Escherichia coli. J Antimicrob Chemother 66 (2011) 2057-60
Bohnert J, Szymaniak-Vits M, Schuster S, Kern WV. Determination of real-time efflux phenotypes in Escherichia coli AcrB binding pocket phenylalanine mutants using a 1,2´-dinaphthylamine efflux assay. PLoS One 6 (2011) e21196.
Martins A, Iversenc C, Rodrigues L, Spengler G, Ramosa J, Kern WV, Couto I, Viveiros M, Fanning S, Pagès JM, Amaral L. AcrAB mediated MDR phenotype is maintained after efflux pump genes and their two regulators have restored wild type activities. Int J Antimicrob Agents 34 (2009) 602-4.
Rodrigues L, Sampaio D, Couto I, Machado D, Kern WV, Amaral L, Viveiros M. The role played by efflux pumps in macrolide resistance in Mycobacterium avium complex. Int J Antimicrob Agents 34 (2009) 529-33.
Rieg S, Huth A, Kalbacher H, Kern WV. Resistance against antimicrobial peptides is independent of Escherichia coli AcrAB, Pseudomonas aeruginosa MexAB and Staphylococcus aureus NorA efflux pumps. Int J Antimicrob Agents 33 (2009) 174-6.
Wehmeier C, Schuster S, Fähnrich E, Kern WV, Bohnert JA. Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance. Antimicrob Agents Chemother 53 (2009) 329-30.
Kern WV, Frank U. Serious hospital infections – the burden and impact of resitsance. Eur Infect Dis 3 (2009) 65-9.
Meyer E, Serr A, Schneider C, Utzolino S, Kern WV, Scholz R, Dettenkofer M. Should we screen patients for extended-spectrum beta-lactamase-producing enterobacteriaceae in intensive care units?
Bohnert JA, Schuster S, Seeger MA, Fähnrich E, Pos KM, Kern WV. Site-directed mutagenesis reveals putative substrate binding residues in the Escherichia coli RND efflux pump AcrB. J Bacteriol 190 (2008) 8225-9.
Viveiros M, Martins A, Paixao L, Rodrigues L, Martins M, Couto I, Fähnrich E, Kern WV, Amaral L. Demonstration of intrinsic efflux activity of Escherichia coli K-12 AG100 by an automated ethidium brmide method. Int J Antimicrob Agents 31 (2008) 458-62.
Rodrigues L, Wagner D, Viveiros M, Sampaio D, Couto I, Vavra M, Kern WV, Amaral L. Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis. J Antimicrob Chemother 61 (2008) 1076-82.
Mahamoud A, Chevalier J, Alibert-Franco S, Kern WV, Pagès JM. Antibiotic efflux pumps in Gram-negative bacteria, the inhibitor response strategy. J Antimicrob Chemother 59 (2007) 1223-1229.
Schumacher A, Trittler R, Bohnert JA, Kümmerer K, Pagès JM, Kern WV. Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation. J Antimicrob Chemother 59 (2007) 1261-4.
Bohnert JA, Schuster S, Fähnrich E, Trittler R, Kern WV. Altered spectrum of multidrug resistance associated with a single point mutation in the Escherichia coli RND type MDR efflux pump YhiV (MdtF). J Antimicrob Chemother 59 (2007) 1216-22.
Kern WV, Steinke P, Schumacher A, Schuster S, von Baum H, Bohnert JA. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. J Antimicrob Chemother 57 (2006) 339-43.
Schumacher A, Steinke P, Bohnert JA, Akova M, Jonas D, Kern WV. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Enterobacteriaceae other than E. coli. J Antimicrob Chemother 57 (2006) 344-8.
Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, Reuter S, von Baum H, Marre R. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenuc patients with leukemia. Eur J Clin Microbiol Infect Dis 24 (2005) 111-8.
Pannek S, Higgins PG, Steinke P, Jonas D, Akova M, Bohnert JA, Seifert H, Kern WV. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginin-ß-naphthylamide. J Antimicrob Chemother 57 (2006) 970-4.
Kern WV, Steib-Bauert M, de With K, Reuter S, Bertz H, Frank U, von Baum H. Fluoroquinolone consumption and resistance in haematology-oncology patients – ecological analysis in two university hospitals 1999-2002. J Antimicrob Chemother 55 (2005) 57-60.
Bohnert J, Kern WV. Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps. Antimicrob Agents Chemother 49 (2005) 849-52.
